Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P07306
UPID:
ASGR1_HUMAN
Alternative names:
C-type lectin domain family 4 member H1; Hepatic lectin H1
Alternative UPACC:
P07306; I3L1X1
Background:
Asialoglycoprotein receptor 1, also known as C-type lectin domain family 4 member H1 or Hepatic lectin H1, plays a crucial role in the endocytosis of plasma glycoproteins by recognizing and binding to terminal galactose and N-acetylgalactosamine units. This process involves the internalization and transport of the receptor-ligand complex to sorting organelles, where they are separated, allowing the receptor to return to the cell surface.
Therapeutic significance:
Understanding the role of Asialoglycoprotein receptor 1 could open doors to potential therapeutic strategies.